| 1 |
35516457 | Characterization of a Pyroptosis-Related Signature for Prognosis Prediction and Immune Microenvironment Infiltration in Prostate Cancer. | 2022 |
1 |
| 2 |
33930312 | Evaluation of TMB as a predictive biomarker in patients with solid cancers treated with anti-PD-1/CTLA-4 combination immunotherapy. | 2021 May 10 |
1 |
| 3 |
31502147 | Measuring Tumor Mutational Burden Using Whole-Exome Sequencing. | 2020 |
1 |
| 4 |
32000815 | Targeted literature review on use of tumor mutational burden status and programmed cell death ligand 1 expression to predict outcomes of checkpoint inhibitor treatment. | 2020 Jan 30 |
1 |
| 5 |
32586938 | Tumor Mutational Burden, Toxicity, and Response of Immune Checkpoint Inhibitors Targeting PD(L)1, CTLA-4, and Combination: A Meta-regression Analysis. | 2020 Sep 15 |
2 |
| 6 |
32810393 | TERT mutations correlate with higher TMB value and unique tumor microenvironment and may be a potential biomarker for anti-CTLA4 treatment. | 2020 Oct |
2 |
| 7 |
29657128 | Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer. | 2018 May 14 |
2 |
| 8 |
28835386 | Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers. | 2017 Nov |
1 |